Drug Trial Radar · NCT01364064
Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Last checked: Nov 20, 2026Latest source record: Feb 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,153
Actual
Start
Jan 2007
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- King Faisal Specialist Hospital & Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Radiation Therapy Oncology Group
- First posted
- Jun 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Conditions
- Glioblastoma
Interventions
TMZDrug
Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
Primary outcomes
What the sponsor says the trial is designed to measure.
- safety and efficacyTime frame: 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.